Action Pharma

Contact
actionpharma.com
+4545475000

Action Pharma A/S

Næsseslottet , Dronninggaards Allé 136
2840 Holte
Denmark
+4545475000
actionpharma.com
Contact
Profile Products News
Contact

About Action Pharma

Action Pharma is a privately owned Danish biotech company. The main strategy of Action Pharma is to develop novel drug candidates targeting melanocortin receptors and bring these to clinical proof of concept for subsequent partnering. The drug candidates are first in class and exploit novel mode of action profiles with efficacy that is superior compared to the current market. Action Pharma has a pipeline of several patent protected drug candidates of which two currently are in clinical development and two in late preclinical development.

Read more about Action Pharma
Facts about Action Pharma
  • Focus : Manufacturer
  • Industry : Pharma

Product portfolio of Action Pharma

Product portfolio

Show all

News about Action Pharma

Action Pharma

07-May-2012 | research and development

Abbott to Acquire Action Pharma's Investigational Compound, AP214, in Phase 2b Development for Prevention of Acute Kidney Injury

Abbott and Action Pharma A/S announced that they have entered into an agreement in which Abbott will acquire AP214 from Action Pharma.AP214 is in ...

Read news
Action Pharma

28-Sep-2011 | research and development

Action Pharma’s phase IIb clinical trial with AP214 to prevent kidney injury demonstrates positive top-line results

Action Pharma A/S announced positive top-line results for its phase IIb AP214 trial in patients undergoing major cardiac surgery. The study demonstrated ...

Read news
Action Pharma

09-Aug-2011 | research and development

Last patient completes last visit in Action Pharma’s phase IIb clinical trial with AP214 to prevent kidney injury associated with major cardiac surgery

The final patient has performed the last visit of the study period in Action Pharma’s US and Denmark based phase IIb study. Treatment with AP214 is ...

Read news
Action Pharma

10-May-2011 | research and development

Action Pharma completes dosing in phase IIb clinical trial with AP214 to prevent acute kidney injury associated with cardiac surgery

Action Pharma A/S has completed dosing in a phase IIb clinical trial with its leading development candidate, AP214. Efficacy and safety data are expected ...

Read news
Action Pharma

10-Nov-2010 | research and development

Action Pharma initiates phase IIb clinical trial with AP214 to prevent kidney injury associated with major cardiac surgery

Action Pharma A/S has administered the first dose to the first patient in a phase IIb clinical trial being undertaken in the USA and Denmark with its ...

Read news
Action Pharma

15-Sep-2010 | research and development

Action Pharma obtains positive results in a phase II clinical trial with AP214

Action Pharma A/S has obtained positive safety, tolerability and efficacy results in the second phase II clinical trial (CS005) with its leading ...

Read news
Action Pharma

09-Jun-2010 | research and development

Action Pharma obtains encouraging preliminary results in a phase II clinical trial with AP214

Action Pharma A/S obtained encouraging preliminary blinded results in the second phase II clinical trial (named CS005) with its lead development candidate ...

Read news
Action Pharma

04-Jun-2010 | business & finance

Action Pharma completes EUR 5 million financing round to advance its lead project AP214

Action Pharma A/S has completed an internal financing round of EUR 5 million which is dedicated to advance the Company’s ongoing phase 2a studies, and the ...

Read news
Show more news about Action Pharma

Here you will find Action Pharma A/S